Inflammatory ulcerative colitis is lifelong inflammatory and its manifestation can range from the rectum to the colon it has an inflating prevalence worldwide. At Protheragen, we focus on progressing in the therapy and understanding of rare gastrointestinal diseases, including ulcerative colitis. We provide complete research service development to all clients as a full-service provider and with our vast experience we can meet the unique challenges posed by these diseases.

Introduction to Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory bowel disease (IBD) with an increasing trend of incidence and prevalence. Globally, the incidence of ulcerative colitis, with North America having an annual incidence of 8.8 to 23.1 per 100,000 person-years and Europe having an annual incidence of 0.6 to 24.3 per 100,000 person-years. The common symptoms of Ulcerative colitis include bloody diarrhea, frequent urination, abdominal cramps, fatigue, and fecal incontinence.

Fig.1 Molecular mechanisms of mucosal inflammation in ulcerative colitis. (Porter, R. J., et al., 2020)

Pathogenesis of Ulcerative Colitis

The etiology of the disease comprises interactions of the environment, the immune system, the gut microbiome, and genetic disposition to the disease. Considerable support has been accumulating towards the idea that both environmental and host components have a complex interplay, which increases the risk of developing ulcerative colitis. It is further believed that disease onset is initiated by certain events that compromise the mucosal barrier, disturb the homeostasis of the gut microbiota, and inappropriately activate the immune system in the gut.

Fig.2 Factors increasing susceptibility to ulcerative colitis. (Porter, R. J., et al., 2020)

Therapeutics Development for Ulcerative Colitis

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

At our firm, we have a dedicated team of professionals who focus on providing highly customer-centered service and improving outcomes through innovative solutions. Our services are fully integrated; we offer diagnostic, therapeutic, and disease model development services for ulcerative colitis, which walk clients through every level of therapeutic development, from preclinical studies to post-market surveillance.

Therapeutic Development Services

• Small Molecule Drug
• Cell Therapy Development
• Gene Therapy Development
• Therapeutic Antibody

• Therapeutic Peptide
• Therapeutic Protein
• Microbiome Therapeutic
• More

Animal Model Development Services

Models built from animals are vital in improving the study of ulcerative colitis since they provide insights that aid in therapy and comprehension of the disease. We offer animal model development services by producing custom animal models that foster the development of the relevant pathophysiology of ulcerative colitis for your research purposes.

Genetically Engineering Models

---

Genetic engineering models involve manipulating the genomes of animals to create predispositions to ulcerative colitis. Animals lacking the anti-inflammatory cytokine IL-10 develop spontaneous colonic inflammation under specific conditions.

Induced Disease Models

---

Chemical induction models utilize colitis-inducing chemicals that can reproduce the symptoms of the disease in the host animal.

• Dextran sulfate sodium (DSS)-induced model
• Oxazolone-induced model

Every study design or service offered by Protheragen is scientifically and operationally sound which makes studies as well as pharmacokinetics and drug safety testing services efficient and effective. Reach out to us to find out how our resources and expertise ensure superior outcomes of specific research. If you would like to learn more about our services and pricing, please feel free to contact us.

References

• Porter, Ross J et al. "Ulcerative colitis: Recent advances in the understanding of disease pathogenesis." F1000Research 9 (2020): F1000 Faculty Rev-294.
• Segal, Jonathan P et al. "Ulcerative colitis: an update." Clinical medicine (London, England) 21.2 (2021): 135-139.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.